```
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'BIOSIS' ENTERED AT 15:59:32 ON 21 JUL 2009
Copyright (c) 2009 The Thomson Corporation
FILE 'BIOTECHDS' ENTERED AT 15:59:32 ON 21 JUL 2009
COPYRIGHT (C) 2009 THOMSON REUTERS
FILE 'EMBASE' ENTERED AT 15:59:32 ON 21 JUL 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.
FILE 'USPATFULL' ENTERED AT 15:59:32 ON 21 JUL 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'WPIDS' ENTERED AT 15:59:32 ON 21 JUL 2009
COPYRIGHT (C) 2009 THOMSON REUTERS
=> s (Histidine Tag or His Tag or Poly His Tag)
L1
        24075 (HISTIDINE TAG OR HIS TAG OR POLY HIS TAG)
=> s L1 and (cleav?)
L2
        13726 L1 AND (CLEAV?)
=> s L2 and (transitional metal)
L3
            13 L2 AND (TRANSITIONAL METAL)
=> s L2 and (metal ions)
L4
         1926 L2 AND (METAL IONS)
=> s L3 and L4
L5
            8 L3 AND L4
=> s L3 and (buffer)
L6
            13 L3 AND (BUFFER)
=> s L6 and (reducing agent)
L7
            2 L6 AND (REDUCING AGENT)
=> s L6 and (oxidizing agent)
L8
            0 L6 AND (OXIDIZING AGENT)
=> s L6 and (Copper or Cu or Cobalt or Co)
L9 13 L6 AND (COPPER OR CU OR COB
            13 L6 AND (COPPER OR CU OR COBALT OR CO)
=> s L9 and (hydrogen peroxid or H2O2)
L10
            0 L9 AND (HYDROGEN PEROXID OR H2O2)
=> s L9 and (ascorbate)
L11
            0 L9 AND (ASCORBATE)
=> s L3 and (hydrgen peroxide or ascorbate)
L12
            0 L3 AND (HYDRGEN PEROXIDE OR ASCORBATE)
=> s L3 and (oxidizing agent or agents)
L13
           13 L3 AND (OXIDIZING AGENT OR AGENTS)
=> s L13 and (reducing agent or agents)
L14
           13 L13 AND (REDUCING AGENT OR AGENTS)
=> s L13 and L14
           13 L13 AND L14
L15
=> s 115 and (hydrogen peroxide)
L16 5 L15 AND (HYDROGEN
            5 L15 AND (HYDROGEN PEROXIDE)
=> s L15 and (ascorbate)
L17 0 L15 AND (
            0 L15 AND (ASCORBATE)
=> s L15 and (Copper or Cu or Cobalt or Co)
L18
           13 L15 AND (COPPER OR CU OR COBALT OR CO)
=> dup rem L18
```

=> File .Biotech

FILE 'MEDLINE' ENTERED AT 15:59:32 ON 21 JUL 2009

FILE 'CAPLUS' ENTERED AT 15:59:32 ON 21 JUL 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

```
Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
       Shuman, Marc, San Francisco, CA, UNITED STATES
The Regents of the University of California (U.S. corporation)
       US 20090155248
                         A1 20090618
       US 2008-14067
                            A1 20080114 (12)
RLI
       Continuation of Ser. No. US 2005-254185, filed on 18 Oct 2005, ABANDONED
       Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, Pat. No.
       US 7030231
       Utility
       APPLICÂTION
LREP
       WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA,
       94304-1050, US
Number of Claims: 23
CLMN
ECL
       Exemplary Claim: 1-80
DRWN
       8 Drawing Page(s)
LN.CNT 5204
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       This invention provides a novel membrane-type serine protease
       (designated MT-SP1) elevated expression of which is associated with
       cancer. In one embodiment, this invention provides a method obtaining a
       prognosis or of detecting or staging a cancer in an organism. The method
       involves providing a biological sample from the organism and detecting
       the level of a membrane type serine protease 1 (MT-SP1) in the sample,
       where an elevated level of the membrane-type serine protease, as
       compared to the level of the protease in a biological sample from a
       normal healthy organism indicates the presence or stage of the cancer.
L19 ANSWER 2 OF 13 USPATFULL on STN
       2009:145929 USPATFULL <<LOGINID::20090721>>
       SIALIC ACID ABC TRANSPORTERS IN PROKARYOTES THERAPEUTIC TARGETS
      Gibson, Bradford W., Berkeley, CA, UNITED STATES
MUNSON, Robert S., Hilliard, OH, UNITED STATES
Post, Deborah M., Fairfax, CA, UNITED STATES
BUCK INSTITUTE, Novato, CA, UNITED STATES (U.S. corporation)
      US 20090131524
                            A1 20090521
       US 2006-916975
                             A1 20060531 (11)
       WO 2006-US21202
                                  20060531
                                  20081222 PCT 371 date
PRAI
      US 2005-689151P
                                  20050607 (60)
      Utility
FS
LREP
       APPLICÂTION
       Weaver Austin Villeneuve & Sampson LLP, P.O. BOX 70250, OAKLAND, CA,
      94612-0250, US
CT.MN
      Number of Claims: 39
ECL
      Exemplary Claim: 1
DRWN
       5 Drawing Page(s)
LN.CNT 2903
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       This invention provides a novel bacterial sialic acid transporter that is a member of the family of ABC transporters. The transporter is a
       useful target for pharmaceuticals.
L19 ANSWER 3 OF 13 USPATFULL on STN
       2008:58714 USPATFULL <<LOGINID::20090721>>
       MT-SP1 polypeptides
       Craik, Charles S., San Francisco, CA, UNITED STATES
       Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
       Shuman, Marc, San Francisco, CA, UNITED STATES
       The Regents of the University of California (U.S. corporation)
       US 20080051559
                             A1 20080228
       US 2007-669725
                             A1
RLI
       Division of Ser. No. US 2005-253869, filed on 18 Oct 2005, GRANTED, Pat.
       No. US 7227009 Division of Ser. No. US 1999-410362, filed on 30 Sep
       1999, GRANTED, Pat. No. US 7030231
       Utility
       APPLICATION
LREP
       WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA,
```

PROCESSING COMPLETED FOR L18

L19 ANSWER 1 OF 13 USPATFULL on STN

=> d 119 1-13 bib ab

13 DUP REM L18 (0 DUPLICATES REMOVED)

Craik, Charles S., San Francisco, CA, UNITED STATES

2009:172634 USPATFULL <<LOGINID::20090721>>

Antibodies to MT-SP1 serine protease

L19

AN TΙ

ΙN

PΑ PΙ

AΙ

DT

FS

AB

AN

ΙN PA

ΡI ΑI

DT

AΒ

AN

TΤ

IN

PΑ

ΡI

AΙ

DT

FS

CLMN

94304-1050, US Number of Claims: 16

Exemplary Claim: 1-80

LN.CNT 5329 CAS INDEXING IS AVAILABLE FOR THIS PATENT. This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer. L19 ANSWER 4 OF 13 USPATFULL on STN AN 2007:183634 USPATFULL <<LOGINID::20090721>> Method for assembling a polymer-biologic delivery composition ΙN Turnell, William G., Del Mar, CA, UNITED STATES Parcher, Benjamin W., San Diego, CA, UNITED STATES Charles, Catherine H., Encinitas, CA, UNITED STATES Pabba, Chittari, San Diego, CA, UNITED STATES Vitiello, Maria A., La Jolla, CA, UNITED STATES MediVas, LLC, San Diego, CA, UNITED STATES (U.S. corporation) US 20070160622 A1 20070712 PA ΡI AΙ US 2006-636230 A1 20061207 (11) 20051207 (60) PRAI US 2005-748486P US 2006-858173P 20061110 (60) DT Utility FS APPLICATION LREP DLA PIPER US LLP, 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA, 92121-2133, US CLMN Number of Claims: 71 ECL Exemplary Claim: 3 DRWN 13 Drawing Page(s) LN.CNT 4175 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AΒ A one-step method for assembly of delivery compositions for one or more antigens or therapeutic biologics is based on non-covalent affinity capture of molecules from solution using a biodegradable polymer having functional groups to which the affinity ligand binds. The polymer-bound affinity complex, which includes the molecule(s) of interest is then recovered from the reaction solution, for example, by size exclusion filtration, to yield the assembled delivery composition. The affinity ligand can be a monoclonal antibody or a metal affinity ligand with bound metal transition ion. The assembled delivery compositions can be formulated as polymer particles, which can then be lyophilized and reconstituted for in vivo delivery of the non-covalently complexed antigen(s) or therapeutic biologic(s) with substantial native activity. L19 ANSWER 5 OF 13 USPATFULL on STN 2006:308189 USPATFULL <<LOGINID::20090721>> ΑN Methods of high-throughput screening for internalizing antibodies IN Marks, James D., Kensington, CA, UNITED STATES Nielsen, Ulrik B., Brookline, MA, UNITED STATES Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES PA PI The Regents of the University of California (U.S. corporation) US 20060263801 A1 20061123 ΑI US 2006-361312 A1 20060224 (11) RLI Division of Ser. No. US 2001-981636, filed on 16 Oct 2001, GRANTED, Pat. No. US 7045283 US 2000-241279P PRAI 20001018 (60) DT APPLICATION FS LREP QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501, US CLMN Number of Claims: 24 ECL Exemplary Claim: 1-43 DRWN 8 Drawing Page(s) LN.CNT 2216 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and iii) detecting the reporter within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized.

L19 ANSWER 6 OF 13 USPATFULL on STN

DRWN

8 Drawing Page(s)

2006:280987 USPATFULL << LOGINID::20090721>> COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND OTHER MATERIALS, AND METHODS OF MAKING AND USING THE SAME ΙN Bolotin, Elijah M., Kirkland, WA, UNITED STATES ΡI US 20060239924 A1 20061026 AΙ US 2006-428803 A1 20060705 (11) RLI Continuation of Ser. No. US 2003-378100, filed on 27 Feb 2003, PENDING PRAI US 2002-360350P 20020227 (60) DT Utility FS APPLICATION LREP DARBY & DARBY P.C., P.O. BOX 5257, NEW YORK, NY, 10150-5257, US CLMN Number of Claims: 25 Exemplary Claim: 1 DRWN 4 Drawing Page(s) LN.CNT 2631 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AΒ In part, the present invention is directed to biocompatible compositions comprising a carrier with a first metal binding domain, a metal ion, an active agent with second metal binding domain and optionally a protective chain covalently attached to the polymeric carrier. L19 ANSWER 7 OF 13 USPATFULL on STN AN 2006:124247 USPATFULL <<LOGINID::20090721>> MT-SP1 POLYNUCLEOTIDES AND POLYPEPTIDES ΙN Craik, Charles S., San Francisco, CA, UNITED STATES Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES Shuman, Marc, San Francisco, CA, UNITED STATES PA The Regents of the University of California (U.S. corporation) ΡI US 20060104979 A1 20060518 US 7227009 B2 20070605 ΑI US 2005-253869 A1 20051018 (11) RLI Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, PENDING DT Utility FS APPLICATION LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US CLMN Number of Claims: 21 ECL Exemplary Claim: 1-80 DRWN 8 Drawing Page(s) LN.CNT 5095 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AΒ This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer. L19 ANSWER 8 OF 13 USPATFULL on STN AN 2006:117783 USPATFULL <<LOGINID::20090721>> MT-SP1 serine protease ΙN Craik, Charles S., San Francisco, CA, UNITED STATES Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES Shuman, Marc, San Francisco, CA, UNITED STATES The Regents of the University of California (U.S. corporation) PΑ ΡI US 20060099625 A1 20060511 A1 20051018 (11) US 2005-254185 RLI Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, PENDING DT Utility FS APPLICATION LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US CLMN Number of Claims: 21 ECL Exemplary Claim: 1-80 DRWN 8 Drawing Page(s) LN.CNT 5119 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

```
L19 ANSWER 9 OF 13 USPATFULL on STN
AN
      2006:110718 USPATFULL <<LOGINID::20090721>>
      Compositions for treatment with glucagon-like peptide, and methods of
      making and using the same
IN
      Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES
PΙ
      US 20060093660
                         A1 20060504
AΙ
      US 2005-266002
                         A1 20051103 (11)
RLI
      Continuation of Ser. No. US 2005-112879, filed on 22 Apr 2005, PENDING
      Continuation-in-part of Ser. No. US 2003-378100, filed on 27 Feb 2003,
PRAI
      US 2004-564710P
                               20040423 (60)
      US 2002-360350P
                              20020227 (60)
DT
      Utility
FS
      APPLICATION
LREP
      FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT
      BLVD, BOSTON, MA, 02110, US
CLMN
      Number of Claims: 22
ECL
      Exemplary Claim: 1
DRWN
      7 Drawing Page(s)
LN.CNT 3104
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AΒ
      In part, the present invention is directed to compositions comprising a
      carrier with a metal binding domain, a metal ion, and GLP-1.
L19 ANSWER 10 OF 13 USPATFULL on STN
AN
      2006:95221 USPATFULL <<LOGINID::20090721>>
TI
      Membrane type serine protease 1 (MT-SP1) and uses thereof
ΙN
      Craik, Charles S., San Francisco, CA, UNITED STATES
      Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
      Shuman, Marc, San Francisco, CA, UNITED STATES
PΑ
      Catalyst Biosciences, Inc., South San Francisco, CA, UNITED STATES (U.S.
      corporation)
ΡI
      US 7030231
                         B1 20060418
AΙ
      US 1999-410362
                              19990930 (9)
DT
      Utility
FS
      GRANTED
EXNAM Primary Examiner: Helms, Larry R.; Assistant Examiner: Yu, Misook
LREP
      Wilson Sonsini Goodrich & Rosati
CLMN
      Number of Claims: 6
Exemplary Claim: 1
ECL
DRWN
      11 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 5132
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AΒ
      This invention provides a novel membrane-type serine protease
       (designated MT-SP1) elevated expression of which is associated with
      cancer. In one embodiment, this invention provides a method obtaining a
      prognosis or of detecting or staging a cancer in an organism. The method
      involves providing a biological sample from the organism and detecting
      the level of a membrane type serine protease 1 (MT-SP1) in the sample,
      where an elevated level of the membrane-type serine protease, as
      compared to the level of the protease in a biological sample from a
      normal healthy organism indicates the presence or stage of the cancer.
L19 ANSWER 11 OF 13 USPATFULL on STN
      2005:298594 USPATFULL <<LOGINID::20090721>>
AN
      Compositions for treatment with glucagon-like peptide, and methods of
      making and using the same
IN
      Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES
      US 20050260259
                          A1 20051124
      US 2005-112879
                          A1
                               20050422 (11)
      US 2004-564710P
PRAI
                               20040423 (60)
      Utility
FS
LREP
      APPLICATION
      FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT
      BLVD, BOSTON, MA, 02110, US
CLMN
      Number of Claims: 22
ECL
      Exemplary Claim: 1
DRWN
      7 Drawing Page(s)
LN.CNT 3100
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB
      In part, the present invention is directed to compositions comprising a
      carrier with a metal binding domain, a metal ion, and GLP-1.
L19 ANSWER 12 OF 13 USPATFULL on STN
AN
      2003:319225 USPATFULL <<LOGINID::20090721>>
      Compositions for delivery of therapeutics and other materials, and
```

methods of making and using the same

Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES

```
PΙ
      US 20030224974
                         A1 20031204
B2 20061121
      US 2003-378100 A1 20030227 (10)
US 2002-360350P
Utility
PRAI
DT
      Utility
FS
      APPLICATION
LREP
      Patent Group, Foley Hoaq LLP, World Trade Center West, 155 Seaport
      Blvd., Boston, MA, 02210-2600
CT.MN
      Number of Claims: 32
ECL
      Exemplary Claim: 1
DRWN
       4 Drawing Page(s)
LN.CNT 2657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB
      In part, the present invention is directed to compositions comprising a
      carrier with a metal binding domain, a metal ion, and an active agent.
   ANSWER 13 OF 13 USPATFULL on STN 2002:322479 USPATFULL <<LOGINID::20090721>>
L19
AN
      Methods of high-throughput screening for internalizing antibodies
ΙN
      Marks, James D., Kensington, CA, UNITED STATES
      Nielsen, Ulrik B., Brookline, MA, UNITED STATES
Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES
                         A1 20021205
ΡI
      US 20020182643
      US 7045283
                           B2 20060516
AΙ
      US 2001-981636
                           A1 20011016 (9)
PRAI
      US 2000-241279P
                                20001018 (60)
DT
      Utility
FS
      APPLICATION
LREP
      QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA,
       94501
CLMN
      Number of Claims: 72
ECL
      Exemplary Claim: 1
DRWN
       8 Drawing Page(s)
LN.CNT 2405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AΒ
      This invention provides methods of identifying ligands that are
       internalized into a cell. The methods typically involve i) contacting
      the cell with a reporter non-covalently coupled to a ligand; ii)
      dissociating the reporter from the ligand and removing dissociated
      reporter from the surface of the cell; and iii) detecting the reporter
      within said cell (if any is present) where the presence of the reporter
      within said cell indicates that the ligand binds to an internalizing
      receptor and is internalized.
=> d his
     (FILE 'HOME' ENTERED AT 15:59:11 ON 21 JUL 2009)
     FILE 'MEDLINE, CAPLUS, BIOSIS, BIOTECHDS, EMBASE, USPATFULL, WPIDS'
    ENTERED AT 15:59:32 ON 21 JUL 2009
L1
          24075 S (HISTIDINE TAG OR HIS TAG OR POLY HIS TAG)
L2
          13726 S L1 AND (CLEAV?)
L3
             13 S L2 AND (TRANSITIONAL METAL)
L4
           1926 S L2 AND (METAL IONS)
L5
              8 S L3 AND L4
L6
             13 S L3 AND (BUFFER)
L7
              2 S L6 AND (REDUCING AGENT)
L8
              0 S L6 AND (OXIDIZING AGENT)
L9
             13 S L6 AND (COPPER OR CU OR COBALT OR CO)
L10
L11
L12
L13
L14
              0 S L9 AND (HYDROGEN PEROXID OR H2O2)
              0 S L9 AND (ASCORBATE)
              0 S L3 AND (HYDRGEN PEROXIDE OR ASCORBATE)
            13 S L3 AND (OXIDIZING AGENT OR AGENTS)
            13 S L13 AND (REDUCING AGENT OR AGENTS)
L15
            13 S L13 AND L14
L16
             5 S L15 AND (HYDROGEN PEROXIDE)
L17
              0 S L15 AND (ASCORBATE)
L18
             13 S L15 AND (COPPER OR CU OR COBALT OR CO)
             13 DUP REM L18 (0 DUPLICATES REMOVED)
=> d L3 1-13 bib ab
L3
    ANSWER 1 OF 13 USPATFULL on STN
AN
      2009:172634 USPATFULL <<LOGINID::20090721>>
      Antibodies to MT-SP1 serine protease
IN
      Craik, Charles S., San Francisco, CA, UNITED STATES
       Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES
       Shuman, Marc, San Francisco, CA, UNITED STATES
```

PΑ The Regents of the University of California (U.S. corporation) PΙ US 20090155248 A1 20090618 AΙ US 2008-14067 A1 20080114 (12) RLI Continuation of Ser. No. US 2005-254185, filed on 18 Oct 2005, ABANDONED Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, Pat. No. DT Utility FS APPLICATION LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA. 94304-1050, US CLMN Number of Claims: 23 ECL Exemplary Claim: 1-80 DRWN 8 Drawing Page(s) LN.CNT 5204 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AΒ This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer. L3 ANSWER 2 OF 13 USPATFULL on STN AN 2009:145929 USPATFULL <<LOGINID::20090721>> SIALIC ACID ABC TRANSPORTERS IN PROKARYOTES THERAPEUTIC TARGETS ΙN Gibson, Bradford W., Berkeley, CA, UNITED STATES Munson, Robert S., Hilliard, OH, UNITED STATES
Post, Deborah M., Fairfax, CA, UNITED STATES
BUCK INSTITUTE, Novato, CA, UNITED STATES
(U.S. corporation) PΑ ΡI US 20090131524 A1 20090521 ΑI US 2006-916975 A1 20060531 (11) WO 2006-US21202 20060531 20081222 PCT 371 date PRAI US 2005-689151P 20050607 (60) DT Utility FS APPLICATION Weaver Austin Villeneuve & Sampson LLP, P.O. BOX 70250, OAKLAND, CA, LREP 94612-0250, US Number of Claims: 39 CLMN Exemplary Claim: 1 ECL DRWN 5 Drawing Page(s) LN.CNT 2903 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB This invention provides a novel bacterial sialic acid transporter that is a member of the family of ABC transporters. The transporter is a useful target for pharmaceuticals. L3 ANSWER 3 OF 13 USPATFULL on STN ΑN 2008:58714 USPATFULL <<LOGINID::20090721>> MT-SP1 polypeptides ΙN Craik, Charles S., San Francisco, CA, UNITED STATES Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES Shuman, Marc, San Francisco, CA, UNITED STATES PΑ The Regents of the University of California (U.S. corporation) ΡI US 20080051559 A1 20080228 ΑI US 2007-669725 A1 20070131 (11) Division of Ser. No. US 2005-253869, filed on 18 Oct 2005, GRANTED, Pat. No. US 7227009 Division of Ser. No. US 1999-410362, filed on 30 Sep RLI 1999, GRANTED, Pat. No. US 7030231 Utility FS LREP APPLICATION WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA. 94304-1050, US CLMN Number of Claims: 16 ECL Exemplary Claim: 1-80 DRWN 8 Drawing Page(s) LN.CNT 5329 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a

```
normal healthy organism indicates the presence or stage of the cancer.
L3
    ANSWER 4 OF 13 USPATFULL on STN
AN
      2007:183634 USPATFULL << LOGINID::20090721>>
TI
      Method for assembling a polymer-biologic delivery composition
IN
      Turnell, William G., Del Mar, CA, UNITED STATES
      Parcher, Benjamin W., San Diego, CA, UNITED STATES
      Charles, Catherine H., Encinitas, CA, UNITED STATES
      Pabba, Chittari, San Diego, CA, UNITED STATES
      Vitiello, Maria A., La Jolla, CA, UNITED STATES
PΑ
      MediVas, LLC, San Diego, CA, UNITED STATES (U.S. corporation) US 20070160622 Al 20070712
PΙ
AΙ
      US 2006-636230
                          A1 20061207 (11)
PRAI
      US 2005-748486P
                               20051207 (60)
      US 2006-858173P
                               20061110 (60)
DT
      Utility
FS
      APPLICATION
LREP
      DLA PIPER US LLP, 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA,
      92121-2133, US
CLMN
      Number of Claims: 71
ECL
      Exemplary Claim: 1
DRWN
      13 Drawing Page(s)
LN.CNT 4175
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      A one-step method for assembly of delivery compositions for one or more
      antigens or therapeutic biologics is based on non-covalent affinity
      capture of molecules from solution using a biodegradable polymer having
      functional groups to which the affinity ligand binds. The polymer-bound
      affinity complex, which includes the molecule(s) of interest is then
      recovered from the reaction solution, for example, by size exclusion
       filtration, to yield the assembled delivery composition. The affinity
       ligand can be a monoclonal antibody or a metal affinity ligand with
      bound metal transition ion. The assembled delivery compositions can be
      formulated as polymer particles, which can then be lyophilized and
      reconstituted for in vivo delivery of the non-covalently complexed
      antigen(s) or therapeutic biologic(s) with substantial native activity.
L3
    ANSWER 5 OF 13 USPATFULL on STN
AN
      2006:308189 USPATFULL <<LOGINID::20090721>>
      Methods of high-throughput screening for internalizing antibodies
ΙN
      Marks, James D., Kensington, CA, UNITED STATES
      Nielsen, Ulrik B., Brookline, MA, UNITED STATES
      Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES
PΑ
      The Regents of the University of California (U.S. corporation)
ΡI
      US 20060263801
                          A1 20061123
AΙ
      US 2006-361312
                          A1 20060224 (11)
      Division of Ser. No. US 2001-981636, filed on 16 Oct 2001, GRANTED, Pat.
RLI
      No. US 7045283
PRAI
      US 2000-241279P
                               20001018 (60)
      Utility
DT
FS
LREP
      APPLICATION
      QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA,
      94501, US
CLMN
      Number of Claims: 24
ECL
      Exemplary Claim: 1-43
DRWN
      8 Drawing Page(s)
LN.CNT 2216
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB
      This invention provides methods of identifying ligands that are
      internalized into a cell. The methods typically involve i) contacting
       the cell with a reporter non-covalently coupled to a ligand; ii)
      dissociating the reporter from the ligand and removing dissociated
      reporter from the surface of the cell; and iii) detecting the reporter
      within said cell (if any is present) where the presence of the reporter
      within said cell indicates that the ligand binds to an internalizing
      receptor and is internalized.
L3
    ANSWER 6 OF 13 USPATFULL on STN
      2006:280987 USPATFULL <<LOGINID::20090721>>
AN
      COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND OTHER MATERIALS, AND
      METHODS OF MAKING AND USING THE SAME
IN
      Bolotin, Elijah M., Kirkland, WA, UNITED STATES
PΙ
      US 20060239924
                         A1 20061026
AΙ
      US 2006-428803
                          A1 20060705 (11)
RLI
      Continuation of Ser. No. US 2003-378100, filed on 27 Feb 2003, PENDING
PRAI
      US 2002-360350P
                               20020227 (60)
DT
      Utility
FS
      APPLICATION
LREP
      DARBY & DARBY P.C., P.O. BOX 5257, NEW YORK, NY, 10150-5257, US
```

DRWN 4 Drawing Page(s) LN.CNT 2631 CAS INDEXING IS AVAILABLE FOR THIS PATENT. In part, the present invention is directed to biocompatible compositions comprising a carrier with a first metal binding domain, a metal ion, an active agent with second metal binding domain and optionally a protective chain covalently attached to the polymeric carrier. ANSWER 7 OF 13 USPATFULL on STN 2006:124247 USPATFULL <<LOGINID::20090721>> MT-SP1 POLYNUCLEOTIDES AND POLYPEPTIDES Craik, Charles S., San Francisco, CA, UNITED STATES Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES Shuman, Marc, San Francisco, CA, UNITED STATES The Regents of the University of California (U.S. corporation) US 20060104979 A1 20060518 B2 20070605 US 7227009 20051018 (11) US 2005-253869 A1 RLI Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, PENDING Utility APPLICATION LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US CLMN Number of Claims: 21 ECL Exemplary Claim: 1-80 DRWN 8 Drawing Page(s) LN.CNT 5095 CAS INDEXING IS AVAILABLE FOR THIS PATENT. This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer. ANSWER 8 OF 13 USPATFULL on STN 2006:117783 USPATFULL <<LOGINID::20090721>> MT-SP1 serine protease Craik, Charles S., San Francisco, CA, UNITED STATES Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES Shuman, Marc, San Francisco, CA, UNITED STATES The Regents of the University of California (U.S. corporation) US 20060099625 A1 20060511 20051018 (11) US 2005-254185 A1 Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, PENDING RLI Utility APPLICATION LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA. 94304-1050, US CLMN Number of Claims: 21 ECL Exemplary Claim: 1-80 DRWN 8 Drawing Page(s) LN.CNT 5119 CAS INDEXING IS AVAILABLE FOR THIS PATENT. This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample. where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer. ANSWER 9 OF 13 USPATFULL on STN 2006:110718 USPATFULL <<LOGINID::20090721>> Compositions for treatment with glucagon-like peptide, and methods of making and using the same Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES US 20060093660 A1 20060504 US 2005-266002 A1 20051103 (11) RLI Continuation of Ser. No. US 2005-112879, filed on 22 Apr 2005, PENDING

Continuation-in-part of Ser. No. US 2003-378100, filed on 27 Feb 2003,

CLMN

ECL

L3

AN

ΤI

IN

PA

PΙ

ΑI

FS

AB

L3

AN

IN

PΑ

ΡI

AΙ

FS

AΒ

L3

AN TI

IN

PΙ

AΙ

PENDING

Number of Claims: 25

Exemplary Claim: 1

PRAI DT FS LREP	BLVD, BOSTON, MA, 02110	20040423 (60) 20020227 (60) GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT , US
	Number of Claims: 22 Exemplary Claim: 1 7 Drawing Page(s) T 3104	
AB	NDEXING IS AVAILABLE FOR ' In part, the present in carrier with a metal bi	THIS PATENT. vention is directed to compositions comprising a nding domain, a metal ion, and GLP-1.
L3 AN TI IN	Craik, Charles S., San Takeuchi, Toshihiko, Sa Shuman, Marc, San Franc	<pre>cLOGINID::20090721>> ctease 1 (NT-SF1) and uses thereof Francisco, CA, UNITED STATES n Francisco, CA, UNITED STATES</pre>
PI AI DT	US 7030231 B1 US 1999-410362 Utility	20060418 19990930 (9)
FS EXNAM LREP CLMN ECL	Wilson Sonsini Goodrich Number of Claims: 6 Exemplary Claim: 1	
	11 Drawing Figure(s); 8 T 5132	
AB	(designated MT-SF1) ele- cancer. In one embodime: prognosis or of detecti: involves providing a bi- the level of a membrane where an elevated level compared to the level o normal healthy organism	a novel membrane-type serine protease vated expression of which is associated with nt, this invention provides a method obtaining a mg or staging a cancer in an organism. The method ological sample from the organism and detecting type serine protease 1 (MT-SPI) in the sample, of the membrane-type serine protease, as f the protease in a biological sample from a indicates the presence or stage of the cancer.
AN TI IN PI AI	making and using the sa Bolotin, Elijah M., Buf US 20050260259 A1 US 2005-112879 A1	<pre><<loginid::20090721>> ent with glucagon-like peptide, and methods of me falo Grove, II, UNITED STATES 20051124 20050422 (11)</loginid::20090721></pre>
PRAI DT	US 2004-564710P Utility	20040423 (60)
FS LREP CLMN	BLVD, BOSTON, MA, 02110 Number of Claims: 22	GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT, US
ECL DRWN	Exemplary Claim: 1 7 Drawing Page(s)	
	T 3100 NDEXING IS AVAILABLE FOR ' In part, the present in carrier with a metal bi	THIS PATENT. vention is directed to compositions comprising a nding domain, a metal ion, and GLP-1.
L3 ; AN TI	ANSWER 12 OF 13 USPATFULL 2003:319225 USPATFULL Compositions for delive methods of making and u	< <loginid::20090721>> ry of therapeutics and other materials, and</loginid::20090721>
IN PI AI		falo Grove, IL, UNITED STATES 20031204 20061121 20030227 (10)
PRAI	US 2002-360350P Utility	20020227 (60)
FS LREP	APPLICATION Patent Group, Foley Hoad Blvd., Boston, MA, 0221	g LLP, World Trade Center West, 155 Seaport 0-2600
CLMN ECL	Number of Claims: 32 Exemplary Claim: 1	
DRWN	4 Drawing Page(s)	

```
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB
       In part, the present invention is directed to compositions comprising a
       carrier with a metal binding domain, a metal ion, and an active agent.
L3
    ANSWER 13 OF 13 USPATFULL on STN
ΑN
       2002:322479 USPATFULL <<LOGINID::20090721>>
       Methods of high-throughput screening for internalizing antibodies
IN
       Marks, James D., Kensington, CA, UNITED STATES
       Nielsen, Ulrik B., Brookline, MA, UNITED STATES
       Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES
ΡI
       US 20020182643
                           A1
                                20021205
       US 7045283
                           B2 20060516
AΙ
       US 2001-981636
                           A1 20011016 (9)
PRAI
DT
       US 2000-241279P
                                 20001018 (60)
       Utility
FS
       APPLICATION
LREP
       QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA,
       94501
CLMN
       Number of Claims: 72
ECL
       Exemplary Claim: 1
DRWN
       8 Drawing Page(s)
LN.CNT 2405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       This invention provides methods of identifying ligands that are
       internalized into a cell. The methods typically involve i) contacting
       the cell with a reporter non-covalently coupled to a ligand; ii)
       dissociating the reporter from the ligand and removing dissociated
       reporter from the surface of the cell; and iii) detecting the reporter
       within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing
       receptor and is internalized.
=> d L5 1-8 bib ab
L5
    ANSWER 1 OF 8 USPATFULL on STN
AN
       2009:145929 USPATFULL <<LOGINID::20090721>>
       SIALIC ACID ABC TRANSPORTERS IN PROKARYOTES THERAPEUTIC TARGETS
ΙN
       Gibson, Bradford W., Berkeley, CA, UNITED STATES
       Munson, Robert S., Hilliard, OH, UNITED STATES
Post, Deborah M., Fairfax, CA, UNITED STATES
PA
       BUCK INSTITUTE, Novato, CA, UNITED STATES (U.S. corporation)
       US 20090131524
                           A1 20090521
ΡI
ΑI
       US 2006-916975
                            A1 20060531 (11)
       WO 2006-US21202
                                 20060531
                                 20081222 PCT 371 date
PRAI
      US 2005-689151P
                                 20050607 (60)
DT
      Utility
FS
LREP
       APPLICATION
       Weaver Austin Villeneuve & Sampson LLP, P.O. BOX 70250, OAKLAND, CA,
      94612-0250, US
CT.MN
       Number of Claims: 39
ECL.
       Exemplary Claim: 1
DRWN
       5 Drawing Page(s)
LN.CNT 2903
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       This invention provides a novel bacterial sialic acid transporter that is a member of the family of ABC transporters. The transporter is a
AΒ
       useful target for pharmaceuticals.
L5
    ANSWER 2 OF 8 USPATFULL on STN
AN
       2007:183634 USPATFULL << LOGINID::20090721>>
       Method for assembling a polymer-biologic delivery composition
IN
       Turnell, William G., Del Mar, CA, UNITED STATES
       Parcher, Benjamin W., San Diego, CA, UNITED STATES
       Charles, Catherine H., Encinitas, CA, UNITED STATES
       Pabba, Chittari, San Diego, CA, UNITED STATES
       Vitiello, Maria A., La Jolla, CA, UNITED STATES
PΑ
       MediVas, LLC, San Diego, CA, UNITED STATES (U.S. corporation)
                         A1 20070712
       US 20070160622
                            A1 20061207 (11)
AΙ
       US 2006-636230
PRAI
       US 2005-748486P
                                 20051207 (60)
       US 2006-858173P
                                 20061110 (60)
DT
       Utility
FS
       APPLICATION
LREP
       DLA PIPER US LLP, 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA,
```

LN.CNT 2657

92121-2133, US Number of Claims: 71

Exemplary Claim: 1 DRWN 13 Drawing Page(s) LN.CNT 4175 CAS INDEXING IS AVAILABLE FOR THIS PATENT. A one-step method for assembly of delivery compositions for one or more antigens or therapeutic biologics is based on non-covalent affinity capture of molecules from solution using a biodegradable polymer having functional groups to which the affinity ligand binds. The polymer-bound affinity complex, which includes the molecule(s) of interest is then recovered from the reaction solution, for example, by size exclusion filtration, to yield the assembled delivery composition. The affinity ligand can be a monoclonal antibody or a metal affinity ligand with bound metal transition ion. The assembled delivery compositions can be formulated as polymer particles, which can then be lyophilized and reconstituted for in vivo delivery of the non-covalently complexed antigen(s) or therapeutic biologic(s) with substantial native activity. L5 ANSWER 3 OF 8 USPATFULL on STN 2006:308189 USPATFULL <<LOGINID::20090721>> ΑN Methods of high-throughput screening for internalizing antibodies Marks, James D., Kensington, CA, UNITED STATES Nielsen, Ulrik B., Brookline, MA, UNITED STATES Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES ΙN PΑ The Regents of the University of California (U.S. corporation) A1 20061123 ΡI US 20060263801 AΙ US 2006-361312 A1 20060224 (11) RLI Division of Ser. No. US 2001-981636, filed on 16 Oct 2001, GRANTED, Pat. No. US 7045283 PRAI US 2000-241279P 20001018 (60) DT Utility APPLICATION FS QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, LREP 94501, US CLMN Number of Claims: 24 ECL Exemplary Claim: 1-43 DRWN 8 Drawing Page(s) LN.CNT 2216 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AΒ This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and iii) detecting the reporter within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized. L5 ANSWER 4 OF 8 USPATFULL on STN ΑN 2006:280987 USPATFULL <<LOGINID::20090721>> COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND OTHER MATERIALS, AND METHODS OF MAKING AND USING THE SAME IN Bolotin, Elijah M., Kirkland, WA, UNITED STATES ΡI US 20060239924 A1 20061026 AΙ A1 20060705 (11) US 2006-428803 RLI Continuation of Ser. No. US 2003-378100, filed on 27 Feb 2003, PENDING PRAI US 2002-360350P 20020227 (60) DT Utility FS APPLICATION LREP DARBY & DARBY P.C., P.O. BOX 5257, NEW YORK, NY, 10150-5257, US Number of Claims: 25 Exemplary Claim: 1 DRWN 4 Drawing Page(s) LN.CNT 2631 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB In part, the present invention is directed to biocompatible compositions comprising a carrier with a first metal binding domain, a metal ion, an active agent with second metal binding domain and optionally a protective chain covalently attached to the polymeric carrier. L5 ANSWER 5 OF 8 USPATFULL on STN 2006:110718 USPATFULL <<LOGINID::20090721>> ΑN Compositions for treatment with glucagon-like peptide, and methods of making and using the same IN Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES PΙ US 20060093660 A1 20060504 AΙ US 2005-266002 A1 20051103 (11) Continuation of Ser. No. US 2005-112879, filed on 22 Apr 2005, PENDING RLI Continuation-in-part of Ser. No. US 2003-378100, filed on 27 Feb 2003,

PENDING

PRAI	US 2004-564710P 20040423 (60) US 2002-360350P 20020227 (60)
DT	Utility
FS LREP	APPLICATION FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT
LKLF	BLVD, BOSTON, MA, 02110, US
CLMN	Number of Claims: 22
ECL DRWN	Exemplary Claim: 1 7 Drawing Page(s)
LN.CNT	3104
CAS INI AB	DEXING IS AVAILABLE FOR THIS PATENT. In part, the present invention is directed to compositions comprising a
	carrier with a metal binding domain, a metal ion, and GLP-1.
L5 AN	NSWER 6 OF 8 USPATFULL ON STN
AN	ISWER 6 OF 8 USPATFULL ON STN 2005:298594 USPATFULL < <loginid::20090721>></loginid::20090721>
TI	Compositions for treatment with glucagon-like peptide, and methods of making and using the same
IN	Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES
PI AI	US 20050260259 A1 20051124 US 2005-112879 A1 20050422 (11)
PRAI	US 2004-564710P 20040423 (60)
DT FS	Utility APPLICATION
LREP	FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT
CLMN	BLVD, BOSTON, MA, 02110, US Number of Claims: 22
ECL	Exemplary Claims: 1
DRWN LN.CNT	7 Drawing Page(s)
	SIOU DEXING IS AVAILABLE FOR THIS PATENT.
AB	In part, the present invention is directed to compositions comprising a
	carrier with a metal binding domain, a metal ion, and GLP-1.
L5 AN AN	NSWER 7 OF 8 USPATFULL on STN 2003:319225 USPATFULL < <loginid::20090721>></loginid::20090721>
TI	Compositions for delivery of therapeutics and other materials, and
737	methods of making and using the same
IN PI	Bolotin, Elijah M., Buffalo Grove, IL, UNITED STATES US 20030224974 Al 20031204
	US 7138105 B2 20061121
AI PRAI	US 2003-378100 A1 20030227 (10) US 2002-360350P 20020227 (60)
DT	Utility
FS LREP	APPLICATION Patent Group, Foley Hoag LLP, World Trade Center West, 155 Seaport
	Blvd., Boston, MA, 02210-2600
CLMN ECL	Number of Claims: 32 Exemplary Claim: 1
DRWN	4 Drawing Page(s)
LN.CNT	2657 DEXING IS AVAILABLE FOR THIS PATENT.
AB	In part, the present invention is directed to compositions comprising a
	carrier with a metal binding domain, a metal ion, and an active agent.
L5 AN	NSWER 8 OF 8 USPATFULL on STN
AN TI	2002:322479 USPATFULL < <loginid::20090721>> Methods of high-throughput screening for internalizing antibodies</loginid::20090721>
IN	Marks, James D., Kensington, CA, UNITED STATES
	Nielsen, Ulrik B., Brookline, MA, UNITED STATES Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES
PI	US 20020182643 A1 20021205
3 T	US 7045283 B2 20060516 US 2001-981636 A1 20011016 (9)
AI PRAI	US 2001-981636 A1 20011016 (9) US 2000-241279P 20001018 (60)
DT	Utility
FS LREP	APPLICATION QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA,
	94501
CLMN ECL	Number of Claims: 72 Exemplary Claim: 1
DRWN	8 Drawing Page(s)
LN.CNT	2405 DEXING IS AVAILABLE FOR THIS PATENT.
AB	This invention provides methods of identifying ligands that are
	internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii)
	dissociating the reporter from the ligand and removing dissociated
	reporter from the surface of the cell; and iii) detecting the reporter

20001018 (60) PRAI US 2000-241279P DT Utility FS APPLICATION OUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, LREP 94501, US CLMN Number of Claims: 24 ECL Exemplary Claim: 1-43 DRWN 8 Drawing Page(s) LN.CNT 2216 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and iii) detecting the reporter within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing receptor and is internalized. L7 ANSWER 2 OF 2 USPATFULL on STN AN 2002:322479 USPATFULL <<LOGINID::20090721>> Methods of high-throughput screening for internalizing antibodies Marks, James D., Kensington, CA, UNITED STATES ΙN Nielsen, Ulrik B., Brookline, MA, UNITED STATES Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES A1 20021205 ΡI US 20020182643

Division of Ser. No. US 2001-981636, filed on 16 Oct 2001, GRANTED, Pat.

within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing

Methods of high-throughput screening for internalizing antibodies Marks, James D., Kensington, CA, UNITED STATES Nielsen, Ulrik B., Brookline, MA, UNITED STATES Kirpotin, Dimitri B., San Francisco, CA, UNITED STATES

The Regents of the University of California (U.S. corporation)

receptor and is internalized.

ANSWER 1 OF 2 USPATFULL on STN

2006:308189 USPATFULL <<LOGINID::20090721>>

A1 20061123

B2 20060516

A1 20011016 (9)

20001018 (60)

This invention provides methods of identifying ligands that are internalized into a cell. The methods typically involve i) contacting the cell with a reporter non-covalently coupled to a ligand; ii) dissociating the reporter from the ligand and removing dissociated reporter from the surface of the cell; and iii) detecting the reporter within said cell (if any is present) where the presence of the reporter within said cell indicates that the ligand binds to an internalizing

OUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA,

A1 20060224 (11)

=> d L7 1-2 bib ab

US 20060263801

US 2006-361312

No. US 7045283

L7 AN

TI IN

PΑ

PΙ

ΑI

RLI

AΙ

FS

PRAI DT

LREP

CLMN

LN.CNT 2405

ECL DRWN

AB

IN

PΑ

=> d L16 1-5 bib ab L16 ANSWER 1 OF 5 USPATFULL ON STN
AN 2009:172634 USPATFULL <<LOGINID::20090721>>

US 7045283

APPLICATION

Utility

94501

US 2001-981636

US 2000-241279P

Number of Claims: 72 Exemplary Claim: 1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

receptor and is internalized.

8 Drawing Page(s)

Craik, Charles S., San Francisco, CA, UNITED STATES Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES Shuman, Marc, San Francisco, CA, UNITED STATES The Regents of the University of California (U.S. corporation) US 20090155248

Antibodies to MT-SP1 serine protease

A1 20090618

ΡI AΙ US 2008-14067 A1 20080114 (12) RLI

Continuation of Ser. No. US 2005-254185, filed on 18 Oct 2005, ABANDONED Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, Pat. No.

US 7030231 DT Utility FS APPLICATION LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US CLMN Number of Claims: 23 ECL Exemplary Claim: 1-80 DRWN 8 Drawing Page(s) LN.CNT 5204 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AΒ This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer. L16 ANSWER 2 OF 5 USPATFULL on STN 2008:58714 USPATFULL <<LOGINID::20090721>> AN ΤI MT-SP1 polypeptides ΙN Craik, Charles S., San Francisco, CA, UNITED STATES Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES Shuman, Marc, San Francisco, CA, UNITED STATES PA The Regents of the University of California (U.S. corporation) ΡI US 20080051559 A1 20080228 US 2007-669725 Al 20070131 (11)
Division of Ser. No. US 2008-253869, filed on 18 Oct 2005, GRANTED, Pat.
No. US 7227009 Division of Ser. No. US 1999-410362, filed on 30 Sep ΑI RLI 1999, GRANTED, Pat. No. US 7030231 DT Utility FS APPLICATION LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US CLMN Number of Claims: 16 ECL Exemplary Claim: 1-80 DRWN 8 Drawing Page(s) LN.CNT 5329 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AΒ This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer. L16 ANSWER 3 OF 5 USPATFULL on STN AN 2006:124247 USPATFULL <<LOGINID::20090721>> MT-SP1 POLYNUCLEOTIDES AND POLYPEPTIDES ΙN Craik, Charles S., San Francisco, CA, UNITED STATES Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES Shuman, Marc, San Francisco, CA, UNITED STATES PΑ The Regents of the University of California (U.S. corporation) ΡI US 20060104979 A1 20060518 US 7227009 B2 20070605 US 2005-253869 A1 20051018 (11) Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, PENDING RLI DT Utility FS LREP APPLICATION WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA. 94304-1050, US CLMN Number of Claims: 21 ECL Exemplary Claim: 1-80 DRWN 8 Drawing Page(s) LN.CNT 5095 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a

normal healthy organism indicates the presence or stage of the cancer. L16 ANSWER 4 OF 5 USPATFULL on STN AN 2006:117783 USPATFULL << LOGINID::20090721>> TI MT-SP1 serine protease IN Craik, Charles S., San Francisco, CA, UNITED STATES Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES Shuman, Marc, San Francisco, CA, UNITED STATES PΑ The Regents of the University of California (U.S. corporation) ΡI A1 20060511 A1 20051018 (11) US 20060099625 AΙ US 2005-254185 RLI Continuation of Ser. No. US 1999-410362, filed on 30 Sep 1999, PENDING DT Utility FS APPLICATION LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA. 94304-1050, US CLMN Number of Claims: 21 Exemplary Claim: 1-80 ECL DRWN 8 Drawing Page(s) LN.CNT 5119 CAS INDEXING IS AVAILABLE FOR THIS PATENT. This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer. L16 ANSWER 5 OF 5 USPATFULL on STN AN 2006:95221 USPATFULL <<LOGINID::20090721>> Membrane type serine protease 1 (MT-SP1) and uses thereof ΙN Craik, Charles S., San Francisco, CA, UNITED STATES Takeuchi, Toshihiko, San Francisco, CA, UNITED STATES Shuman, Marc, San Francisco, CA, UNITED STATES PΑ Catalyst Biosciences, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation) PΙ US 7030231 B1 20060418 US 1999-410362 19990930 (9) Utility FS GRANTED EXNAM Primary Examiner: Helms, Larry R.; Assistant Examiner: Yu, Misook LREP CLMN Wilson Sonsini Goodrich & Rosati Number of Claims: 6 ECL Exemplary Claim: 1 DRWN 11 Drawing Figure(s); 8 Drawing Page(s) LN.CNT 5132 CAS INDEXING IS AVAILABLE FOR THIS PATENT. AΒ This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as

compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.

---Logging off of STN---

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 16:13:34 ON 21 JUL 2009